NZ594011A - Deoxyactagardine derivatives - Google Patents

Deoxyactagardine derivatives

Info

Publication number
NZ594011A
NZ594011A NZ594011A NZ59401110A NZ594011A NZ 594011 A NZ594011 A NZ 594011A NZ 594011 A NZ594011 A NZ 594011A NZ 59401110 A NZ59401110 A NZ 59401110A NZ 594011 A NZ594011 A NZ 594011A
Authority
NZ
New Zealand
Prior art keywords
deoxyactagardine
infection
derivatives
difficile
microbial
Prior art date
Application number
NZ594011A
Other languages
English (en)
Inventor
Sjoerd Nicolaas Wadman
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Publication of NZ594011A publication Critical patent/NZ594011A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ594011A 2009-01-14 2010-01-12 Deoxyactagardine derivatives NZ594011A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14449009P 2009-01-14 2009-01-14
PCT/GB2010/000042 WO2010082018A1 (en) 2009-01-14 2010-01-12 Deoxyactagardine derivatives

Publications (1)

Publication Number Publication Date
NZ594011A true NZ594011A (en) 2013-12-20

Family

ID=42110329

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ594011A NZ594011A (en) 2009-01-14 2010-01-12 Deoxyactagardine derivatives

Country Status (22)

Country Link
US (2) US8283371B2 (enExample)
EP (1) EP2387580B1 (enExample)
JP (1) JP5719312B2 (enExample)
KR (1) KR20110119699A (enExample)
CN (1) CN102348718B (enExample)
AU (1) AU2010205472B2 (enExample)
CA (1) CA2749278A1 (enExample)
DK (1) DK2387580T3 (enExample)
EA (1) EA021683B1 (enExample)
ES (1) ES2520165T3 (enExample)
HR (1) HRP20141084T1 (enExample)
IL (1) IL213927A0 (enExample)
MX (1) MX2011007313A (enExample)
NZ (1) NZ594011A (enExample)
PL (1) PL2387580T3 (enExample)
PT (1) PT2387580E (enExample)
RS (1) RS53586B1 (enExample)
SG (1) SG172944A1 (enExample)
SI (1) SI2387580T1 (enExample)
TW (1) TWI453029B (enExample)
WO (1) WO2010082018A1 (enExample)
ZA (1) ZA201104991B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
NZ594011A (en) 2009-01-14 2013-12-20 Novacta Biosystems Ltd Deoxyactagardine derivatives
KR20110122139A (ko) 2009-02-04 2011-11-09 노박타 바이오시스템스 리미티드 액타가르딘 유도체
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013507D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201213434D0 (en) 2012-07-27 2012-09-12 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) * 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (enExample) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
PT700998E (pt) 1994-09-12 2004-03-31 Aventis Pharma Gmbh Mersacidina recombinante e metodo para a sua producao
BR9609281A (pt) 1995-06-23 1999-06-15 Ambi Inc Método para o controle de bactérias gram-positivas resistentes a antibióticos e tratamento de infecções
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
JP4188078B2 (ja) 2000-06-28 2008-11-26 スミスクライン ビーチャム ピー エル シー 湿式粉砕法
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US7199230B2 (en) 2002-10-10 2007-04-03 Molichem Medicines, Inc. Nucleic acids encoding duramycin
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
MXPA06000691A (es) 2003-07-18 2006-04-11 Vicuron Pharm Inc Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas.
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
JP2009509519A (ja) 2005-09-27 2009-03-12 ノヴァクタ バイオシステムズ リミティッド ランチビオティックメルサシジンの変種およびそれらの使用
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
WO2008050209A1 (en) 2006-10-27 2008-05-02 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
CA2690267A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
KR20110086582A (ko) 2008-11-24 2011-07-28 센티넬라 파마세티컬즈, 인크. 항균활성이 강화된 란티바이오틱 카르복시아미드 유도체
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
NZ594011A (en) 2009-01-14 2013-12-20 Novacta Biosystems Ltd Deoxyactagardine derivatives
KR20110122139A (ko) 2009-02-04 2011-11-09 노박타 바이오시스템스 리미티드 액타가르딘 유도체

Also Published As

Publication number Publication date
PT2387580E (pt) 2014-10-30
JP2012515195A (ja) 2012-07-05
SI2387580T1 (sl) 2014-11-28
CN102348718A (zh) 2012-02-08
KR20110119699A (ko) 2011-11-02
EP2387580A1 (en) 2011-11-23
ES2520165T3 (es) 2014-11-11
ZA201104991B (en) 2013-10-31
CN102348718B (zh) 2015-06-03
WO2010082018A1 (en) 2010-07-22
CA2749278A1 (en) 2010-07-22
US8741945B2 (en) 2014-06-03
MX2011007313A (es) 2011-08-04
TW201029661A (en) 2010-08-16
US20100179207A1 (en) 2010-07-15
DK2387580T3 (da) 2014-10-13
EP2387580B1 (en) 2014-08-13
HRP20141084T1 (hr) 2015-02-13
US20120277145A1 (en) 2012-11-01
JP5719312B2 (ja) 2015-05-13
IL213927A0 (en) 2011-07-31
EA021683B1 (ru) 2015-08-31
EA201190071A1 (ru) 2012-06-29
SG172944A1 (en) 2011-08-29
AU2010205472B2 (en) 2013-03-14
US8283371B2 (en) 2012-10-09
AU2010205472A1 (en) 2011-07-28
RS53586B1 (sr) 2015-02-27
PL2387580T3 (pl) 2015-01-30
TWI453029B (zh) 2014-09-21

Similar Documents

Publication Publication Date Title
NZ594011A (en) Deoxyactagardine derivatives
MX2020002727A (es) Nuevo uso para tratamiento de infecciones por clostridium difficile.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2010008523A (es) Inhibidores macrociclicos de serina proteasa.
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
GEP20156230B (en) Forms of rifaximin and usage thereof
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
NZ602311A (en) Anti-infective compounds
MX2012002759A (es) Compuestos quimicos.
MX2009009290A (es) Compuestos activos en ppar.
NZ593111A (en) Antibacterial compounds
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MY159324A (en) Sliding sleeve locking mechanisms
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
UA110199C2 (xx) Тверда дисперсія рифаксиміну
MX2012005859A (es) Peptidos lineales especificos del receptor de melanocortina-1.
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
GEP20156346B (en) Imidazole derivatives as pde10a enzyme inhibitors
MX2015006340A (es) Antibioticos macrociclicos de amplio espectro.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 JAN 2017 BY HENRY HUGHES

Effective date: 20140612

LAPS Patent lapsed